CCRT hosts the 9th International Symposium on Translational Research in Oncology

CCRT, Events l


Friday, 30th September, Mezzanine Suite, Herbert Park hotel
Chairs: Prof John Crown & Prof Robert Kerbel
CPD Accreditation: 6 points

Registration from 11:00

11:30-12:00 Development of immune therapies beyond PD-1 and CTLA-4 blockade
Dr Mario Sznol, Yale Cancer Centre

12:00-12:30 Clinical trials of oxygenation agents and antagonists of A2a adenosine receptors to enable tumor rejection by immunotherapies of cancer
Prof Michail Siktkovsky, Northeastern University, Boston

12:30-1:00 Talimogene laherparepvec, first approved oncolytic immunotherapy
Dr Ohrling Katarina, Amgen Inc.

1:00-1:45 Lunch, Herbert Suite

1:45-2:15 Ribociclib – mechanism of action, preclinical and early clinical development
Dr Thomas Bachelot, Centre Leon Berard, Lyon, France

2:15-2:45 Eribulin mechanisms of action: Beyond antimitotic effects to complex changes in tumour biology
Dr Bruce Littlefield, Eisai Inc.

2:45-3:15 The biology of angiogenesis and the challenge of identifying anti-angiogenesis biomarkers in oncology
Dr Annette Byrne, Royal College of Surgeons in Ireland

3:15-3:45 Implications of ‘vessel co-option’ by tumors for antiangiogenic therapy of metastatic disease
Prof Robert Kerbel, Sunnybrook Health Science Centre, Toronto

3:45-4:00 Coffee break, Herbert Suite

4:00-4:30 The PI3K pathway in cancer
Prof Bryan Hennessy, Royal College of Surgeons in Ireland

4:30-5:00 Targeting the IGF signaling network in cancer with the IGF-1/-2 ligand neutralizing antibody BI 836845 – an update
Dr Thomas Bogenrieder, Boehringer Ingelheim

5:00-5:30 Neratinib for treatment of HER2 mutant, non-amplified breast cancers
Dr Alshad Lalani, Puma Biotechnology Inc.

5:30-6:00 A brief TOR of vistusertib: translating the science into the clinic
Dr Christopher Shepherd, AstraZeneca UK Limited

Saturday 1st October, Mezzanine Suite, Herbert Park Hotel
Chairs: Prof John Crown & Prof Robert Kerbel
CPD Accreditation: 3 points

9:00-9:30 Next Generation Sequencing of FFPE samples in development cohorts and a large randomized trial (ER pos HER2 neg breast cancer).
Dr Christer Svedman, Genomic Health

9:30-10:00 Hybrid-capture based liquid biopsy allows the detection of diverse genomic alterations
Dr Judith Müller, NEO New Oncology

10:00-10.30 HER2 testing: Past and present
Prof Mike Press, University of Southern California

10:30-10:50 Coffee break, Herbert Suite

10:50-11:20 Mutant p53 as a target for the treatment of triple-negative breast cancer
Prof Joe Duffy, St Vincent’s University Hospital/University College Dublin

11:20-11:50 Targeting ATR as an attractive anti-cancer approach
Dr John Pollard, Vertex Pharmaceuticals

11:50-12:20 Talazoparib pharmacology: Clinical potential for PARP inhibition and PARP trapping
Dr Vernon Phan, Medivation Inc.

12:20-1:20 Lunch, Herbert Suite

1:20-1:50 Immune sculpting of the breast cancer genome
Prof Lajos Pusztai, Yale Cancer Center Genetics, Genomics and Epigenetics Program

1:50-2:20 Clonal diversity and genomic drivers of exceptional responses
Prof Michael Barrett, Mayo Clinic Cancer Centre, Arizona

2:20-2:50 DNA instability in solid tumours – the key to curing cancer?
Prof Ken O’Byrne, Princess Alexandra Hospital, Queensland University of Technology

2:50-3:10 Coffee break, Herbert Suite

3:10-3:40 Improving cancer therapy via CDK8/19 Mediator kinase
Prof Igor Roninson, University of South Carolina

3:40-4:10 The potential of inecalcitol, a vitamin D receptor agonist, in hematologic malignancies
Dr Remi Delansorne, Hybrigenics

4:10-4:40 Preclinical activity of abemaciclib as a single agent or in combination with anti-mitotic or targeted therapies for breast cancer
Dr Neil O’Brien, Department of Medicine, UCLA

4:40-5:10 Development of palbociclib from pre-clinical assessment to global registration: A paradigm for development of CDK 4/6 inhibitors
Dr Rich Finn, Geffen School of Medicine, UCLA

Leave a Comment


Email* (never published)